Ken‐ichi Aisaki

1.1k citations
27 papers · 879 indexed · h-index 14
Topics
Erythrocyte Function and Pathophysiology (5 papers)Gene expression and cancer classification (4 papers)Cancer Research and Treatments (3 papers)

In The Last Decade

Ken‐ichi Aisaki

26 papers receiving 858 citations

Peers

Ken‐ichi Aisaki
Comparison fields: 5 of 94
  • Molecular Biology 452
  • Oncology 154
  • Pharmacology 117
  • Genetics 116
  • Cancer Research 108
Replace Ja–June Jang with:
Ja–June Jang South Korea
N Sawada Japan
Komal Ramani United States
Hanne Cathrine Bisgaard Denmark
Reiko Makino Japan
Masahiko Shibazaki Japan
Kwi Hye Koh United States
Peihong Zhou United States
Ken‐ichi Aisaki relative to Ja–June Jang South Korea Ja–June Jang's profile →
Citations per field
00.5×1.5×2.4×
Ja–June Jang · 1×
Citations per year

Countries citing papers authored by Ken‐ichi Aisaki

Since Specialization
Citations

This map shows the geographic impact of Ken‐ichi Aisaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken‐ichi Aisaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken‐ichi Aisaki more than expected).

Fields of papers citing papers by Ken‐ichi Aisaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken‐ichi Aisaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken‐ichi Aisaki. The network helps show where Ken‐ichi Aisaki may publish in the future.

Co-authorship network of co-authors of Ken‐ichi Aisaki

This figure shows the co-authorship network connecting the top 25 collaborators of Ken‐ichi Aisaki. A scholar is included among the top collaborators of Ken‐ichi Aisaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken‐ichi Aisaki. Ken‐ichi Aisaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 3
3 47
4 1
5 1
6 6
7 16
8 13
9 72
10 14
11 33
12 10
13 13
14 16
15 35
16 31
17 39
18 73
19 6
20 227

About Ken‐ichi Aisaki

Ken‐ichi Aisaki is a scholar working on Biotechnology, Cancer Research and Molecular Biology, having authored 27 papers that have together received 879 indexed citations. Recurring topics across this work include Erythrocyte Function and Pathophysiology (5 papers), Gene expression and cancer classification (4 papers) and Cancer Research and Treatments (3 papers). The work is most often cited by research in Pharmacology (117 citations), Hepatology (94 citations) and Cancer Research (108 citations). Ken‐ichi Aisaki has collaborated with scholars based in Japan, Australia and Switzerland. Frequent co-authors include Yoji Ikawa, Jun Kanno, Kenjiro Wake, Jialan Shi, Katsuhide Igarashi, Yumiko Saga, Atsushi Suzuki, Iyoko Katoh, Shun‐ichi Kurata and Shuntaro Ikawa. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026